No nodal cutoff in node-positive breast cancer women treated with mastectomy

Breast Cancer Research and Treatment

Volumn 98, Issue 2, 2006, Pages 173-178

  Vinh Hung, V ^a,b   Storme, G ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Adjuvant; AJCC TNM staging; Axillary lymph node; Breast neoplasms; Mastectomy; Prognostic factors; Radiation treatment; SEER; Surgery

Indexed keywords

HORMONE RECEPTOR;

ADJUVANT THERAPY; ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GRADING; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SIZE; CANCER STAGING; DEATH; FEMALE; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MARRIAGE; MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RACE; TUMOR LOCALIZATION;

BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; PROGNOSIS;

EID: 33745895638     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9146-z     Document Type: Article

References (25)

1. White J, Moughan J, Pierce LJ, et al.: Status of postmastectomy radiotherapy in the United States: a patterns of care study. Int J Radiat Oncol Biol Phys 60: 77-85, 2004
2. Ceilley E, Jagsi R, Goldberg S, et al.: Radiotherapy for invasive breast cancer in North America and Europe: results of a survey. Int J Radiat Oncol Biol Phys 61: 365-373, 2005
3. Recht A, Edge SB, Solin LJ, et al.: Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19: 1539-1569, 2001
4. Vinh-Hung V, Burzykowski T, Van de Steene J, et al.: Statistical interaction in the survival analysis of early breast cancer using registry data: role of breast conserving surgery and radiotherapy. Tumori 91: 9-14, 2005 (http://www.tumorionline.it/numeri/pdf/1_05/03-Vinh-Hung%20(9-14).pdf, accessed 3-27-2005)
5. Fisher B, Slack N, Katrych D, et al.: Ten year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 140: 528-534, 1975
6. Fisher ER, Gregorio RM, Redmond C, et al.: Pathologic findings from the national surgical adjuvant breast project. (Protocol no. 4). III. The significance of extranodal extension of axillary metastases. Am J Clin Pathol 65: 439-444, 1976
7. Attiyeh FF, Jensen M, Huvos AG, et al.: Axillary micrometastasis and macrometastasis in carcinoma of the breast. Surg Gynecol Obstet 144: 839-842, 1977
8. Packaud RA, Prosnitz LR, Bobrow SN: Selection of breast cancer patients for adjuvant chemotherapy. Another look at the prognostic importance of involved lymph nodes. JAMA 238: 1034-1036, 1977
9. Contesso G, Rouesse J, Petit JY, et al.: The anatomopathological factors of prognostic value in breast cancer. Bull Cancer 64: 525-536, 1977
10. Fisher B, Wolmark N, Bauer M, et al.: The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 152: 765-772, 1981
11. Rosen PP, Saigo PE, Braun DW, et al.: Prognosis in stage II (T1N1M0) breast cancer. Ann Surg 194: 576-584, 1981
12. van der Hage JA, Putter H, Bonnema J, et al.: Impact of locoregional treatment on the early-stage breast cancer patients: a retrospective analysis. Eur J Cancer 39: 2192-2199, 2003
13. Overgaard M, Nielsen H, Overgaard J: Is the benefit of postmastectomy irradiation limited to patients with 4 or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b & c randomized trials. Abstract 33. Radiother Oncol 73(Suppl 1): S14-S15, 2004
14. Fisher B, Slack NH, Cavanaugh PJ, et al.: Postoperative radiotherapy in the treatment of breast cancer: results of the NSABP clinical trial. Ann Surg 172: 711-732, 1970
15. Martin M, Pienkowski T, Mackey J, et al.: Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352: 2302-2313, 2005
16. EBCTCG Secretariat: Breast cancer survival advantage with radiotherapy. Lancet 356: 1271, 2000
17. Vinh-Hung V, Burzykowski T, Cserni G, et al.: Functional form of the effect of the numbers of axillary nodes on survival in early breast cancer. Int J Oncol 22: 697-704, 2003 (http://147.52.72.117/IJO/2003/volume22/number3/697. pdf, accessed 7-11-2004)
18. National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Public-Use Data (1973-2001), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2004, based on the November 2003 submission. Bethesda, MD, National Cancer Institute, 2004
19. Harlan LC, Abrams J, Warren JL, et al.: Adjuvant therapy for breast cancer: practice patterns of community physicians. J Clin Oncol 20: 1809-1817, 2002
20. Therneau TM, Grambsch PM: Modeling survival data: extending the Cox model. Springer-Verlag, New York, NY, 2000 87-152
21. Du XL: Re: Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. J Natl Cancer Inst 95: 683-685, 2003
22. Du X, Freeman JL, Goodwin JS: Information on radiation treatment in patients with breast cancer: the advantages of the linked Medicare and SEER data. J Clin Epidemiol. 52: 463-470, 1999
23. Cianfrocca M, Goldstein LJ: Operable breast cancer. Curr Treat Options Oncol 2: 157-167, 2001
24. Levine M: Clinical practice guidelines for the care and treatment of breast cancer: adjuvant systemic therapy for node-positive breast cancer (summary of the 2001 update). The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ 164: 644-646, 2001
25. Kunkler I: SUPREMO, an MRC Phase III randomised trial to assess the role of adjuvant chest wall irradiation in 'intermediate risk' operable breast cancer following mastectomy. ISRCTN61145589. Current Controlled Trials 2005 (http://controlled-trials.com/isrctn/trial/%7C/0/61145589.html, accessed 9-2-2005)